These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. March-in rights under the Bayh-Dole Act: the NIH's paper tiger? O'Brien W Seton Hall Law Rev; 2013 Nov; 43(4):1403-32. PubMed ID: 24308083 [No Abstract] [Full Text] [Related]
7. To march in or not to march in. Black CA Nat Med; 2011 Aug; 17(8):921; author reply 921-2. PubMed ID: 21818082 [No Abstract] [Full Text] [Related]
8. A united front. Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888 [No Abstract] [Full Text] [Related]
10. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related]
11. The Fabrazyme shortage--a call to action for metabolic physicians. Sirrs S Mol Genet Metab; 2011 Jan; 102(1):4-5. PubMed ID: 21111645 [TBL] [Abstract][Full Text] [Related]
12. [Orphan drugs and sick patients]. Kristiansen IS; Olsen JA Tidsskr Nor Laegeforen; 2005 Apr; 125(8):992. PubMed ID: 15852066 [No Abstract] [Full Text] [Related]
13. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Linthorst GE; Germain DP; Hollak CE; Hughes D; Rolfs A; Wanner C; Mehta A; Mol Genet Metab; 2011 Jan; 102(1):99-102. PubMed ID: 21123099 [TBL] [Abstract][Full Text] [Related]
14. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
15. Incentives for drug development--the curious case of colchicine. Kesselheim AS; Solomon DH N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164 [No Abstract] [Full Text] [Related]
16. The role of voluntary disease organizations in research and development of orphan drugs. Horansky R Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293 [No Abstract] [Full Text] [Related]
17. AZT patent faces challenges. Am Pharm; 1991 Oct; NS31(10):19. PubMed ID: 1957795 [No Abstract] [Full Text] [Related]
18. Agalsidase: a second look. With hindsight: full data challenge efficacy. Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828 [No Abstract] [Full Text] [Related]
19. A "Duty" to Continue Selling Medicines. Janssen WM Am J Law Med; 2014; 40(4):330-92. PubMed ID: 27530049 [TBL] [Abstract][Full Text] [Related]
20. Patents. NIH declines to march in on pricing AIDS drug. Malakoff D Science; 2004 Aug; 305(5686):926. PubMed ID: 15310867 [No Abstract] [Full Text] [Related] [Next] [New Search]